Heron Therapeuti (HRTX)vsMerck & Company Inc (MRK)
HRTX
Heron Therapeuti
$0.28
-8.44%
HEALTHCARE · Cap: $56.69M
MRK
Merck & Company Inc
$144.52
-2.23%
HEALTHCARE · Cap: $362.27B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 44469% more annual revenue ($67.38B vs $151.18M). MRK leads profitability with a 3.6% profit margin vs -22.5%. MRK earns a higher WallStSmart Score of 42/100 (D).
HRTX
Avoid29
out of 100
Grade: F
MRK
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HRTX.
Margin of Safety
-74.0%
Fair Value
$84.93
Current Price
$144.52
$59.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Strong operational efficiency at 35.2%
Generating 5.5B in free cash flow
Areas to Watch
Trading at 9.5x book value
1.3% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
4.7% revenue growth
ROE of 5.5% — below average capital efficiency
3.6% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : HRTX
HRTX has a balanced fundamental profile.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : HRTX
The primary concerns for HRTX are Price/Book, Revenue Growth, EPS Growth. Debt-to-equity of 26.80 is elevated, increasing financial risk.
Bear Case : MRK
The primary concerns for MRK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 148.4x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
HRTX profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
HRTX carries more volatility with a beta of 1.65 — expect wider price swings.
MRK is growing revenue faster at 4.7% — sustainability is the question.
MRK generates stronger free cash flow (5.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (42/100 vs 29/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Heron Therapeuti
HEALTHCARE · BIOTECHNOLOGY · USA
Heron Therapeutics, Inc., a biotechnology company, is dedicated to developing treatments to address unmet medical needs. The company is headquartered in San Diego, California.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?